ArticleAdvanced healthcare materials2026
Targeting the ARRDC3-DRP1 Axis via hUMSC-Derived Exosomal CRYAB for Neuroprotection in Cerebral Ischemia/Reperfusion Injury.
Article in Advanced healthcare materials, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Cerebral ischemia/reperfusion injury (CIRI) remains a major clinical challenge due to the lack of effective neuroprotective strategies. Here, hUMSC-derived exosomes (H-Exo) were isolated and administered intranasally (15 µg/mouse/day for 3 days) in a mouse middle cerebral artery occlusion/reperfusion (MCAO/R) model. Animals were randomly assigned to three groups: Sham, MCAO/R, and H-Exo-treated MCAO/R mice. H-Exo efficiently penetrated the blood-brain barrier, accumulated within the ischemic penumbra, and was internalized by neurons and glial cells. Treatment with H-Exo markedly improved neurological function both in vivo and in vitro. Mechanistically, H-Exo inhibits neuronal ferroptosis by preserving mitochondrial dynamics and alleviating oxidative stress. Transcriptomic analysis identified ARRDC3 as a previously unrecognized ferroptosis-associated gene that was upregulated after ischemia but suppressed by H-Exo treatment. ARRDC3 exacerbates neuronal ferroptosis by promoting Drp1-dependent mitochondrial fragmentation. Proteomic profiling further identified CRYAB as an abundant exosomal cargo mediating the neuroprotective effects of H-Exo. Pharmacological inhibition of CRYAB with NCI-41356 partially reversed the anti-ferroptotic effects of H-Exo, confirming its essential role. Collectively, this study reveals the CRYAB-ARRDC3-Drp1 axis as a key regulator linking mitochondrial dynamics to ferroptosis and highlights H-Exo as a promising non-invasive therapeutic approach for ischemic stroke.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.